Life Science Compliance Update – Page 8 – Policy & Medicine

Improving Outcomes – Analyzing a Compliance Training Curriculum to Reduce Risk

The Financial Risk of Waiting – 340B, Duplicate Discounts and Diversion

Changing the Rules Again: The MedTech Europe Code & Third-Party Educational Support

Whack a Mole: Pricing Bills Keep Popping Up Everywhere

The Murky Future of Physician Owned Distributorships (“PODs”)?

TEVA – Using Legitimate Distributor Payments to Conceal Bribes

Going Back to the Roots of the False Claims Act – Baxter Settles cGMP Allegations

Project Exclusion: The OIG’s Latest Attempt to Make Its Exclusion Authority Real

Healthcare Reform – Chinese Style

340B and You: Thoughts on Program Oversight for Pharmaceutical Manufacturers